What CJC-1295 actually costs in the UK

If you are trying to find out what CJC-1295 costs in the UK, the honest starting point is that there is no official price to find. CJC-1295 has never held a UK marketing authorisation, and under UK law a product that meets the definition of a medicine cannot be marketed until it is licensed by the MHRA^[2]. No pharmacy stocks it, no GP prescribes it on the NHS, and there is no NICE appraisal and no reimbursement route attached to it. Every price you see quoted is a cash price from the research-chemical market, set by online suppliers who sit outside the medicines system and offer no quality guarantee.

That gap between what readers expect, an NHS price or a private-clinic price, and what actually exists, an unregulated cash market, is the whole story of CJC-1295 pricing in the UK. This article explains why no licensed price exists, what the grey market charges, what pushes the number up or down, and the costs that never show up on the invoice. It is educational and journalistic, not medical or legal advice.

Why there is no NHS price or reimbursement

Two things have to be true before the NHS will pay for a medicine. The first is a marketing authorisation from the MHRA, the UK medicines regulator. Under the Human Medicines Regulations, a product that counts as a medicine cannot be placed on the UK market without that licence, and the MHRA has publicly restated the point while warning firms against promoting unlicensed treatments to the public^[2]. CJC-1295 has never had a licence. The clinical programme that produced its only published human data was run by ConjuChem in the mid-2000s and never reached the Phase 2 or Phase 3 efficacy trials a regulator would need. There is nothing on file for the MHRA to authorise.

The second gatekeeper is the National Institute for Health and Care Excellence (NICE), which decides whether the NHS funds a licensed medicine and under what criteria. That is how access works for a drug like tirzepatide, where a NICE technology appraisal sets the eligibility rules that a patient has to meet. No such appraisal exists for CJC-1295, because NICE appraises licensed medicines, not unlicensed research peptides. There are no NHS-equivalent criteria to satisfy here, because there is no NHS route to begin with. A reader looking for the criterion that would trigger NHS funding is looking for something that was never built.

The NHS can supply an unlicensed medicine in narrow circumstances, through what are called specials. The NHS Specialist Pharmacy Service is clear that this applies only where there is no licensed medicine available to meet a patient's special clinical need, and that cost saving or convenience is not a special clinical need^[3]. A named prescriber also has to take personal responsibility for the quality, safety and effectiveness of the product^[3]. That route exists for cases like a child who cannot swallow a licensed tablet, not for a body-composition peptide ordered online. In practice, no CJC-1295 reaches a UK patient through any NHS channel.

What the research-chemical market is actually selling

With no licensed supply, the only place to buy CJC-1295 in the UK is the grey market: online suppliers who sell it as a research chemical labelled for laboratory use only and not for human consumption^[5]. That label carries no legal weight as a defence, but it is the model the whole market runs on. There is no pharmacist, no prescription, and no batch released against a regulated standard.

There is also a catch specific to this peptide, and it feeds straight into price. CJC-1295 is sold as two different molecules under one name. The version studied in the published human work, CJC-1295 with DAC, carries a linker that binds to albumin in the blood and stretches its half-life to between 5.8 and 8.1 days^[1]. The version most vendors actually ship, CJC-1295 without DAC (also sold as MOD-GRF 1-29), has no linker and clears in roughly half an hour. The two are not interchangeable, and a buyer chasing the multi-day profile from the published studies can pay for one and receive the other without ever knowing.

What a vial costs, and what the price does not tell you

Concrete figures come only from supplier listings, because there is no official price to quote against. In July 2026 one widely referenced international research supplier listed CJC-1295 with DAC in a 5 mg vial at USD 52^[5], and CJC-1295 without DAC in a 5 mg vial at USD 41^[6], both sold for research use only. UK-based research suppliers list the same peptide in a broadly comparable per-vial range in pounds. Treat these as illustrative, not as a number you can rely on: listings change, vendors come and go, and shipping, customs handling and payment in cryptocurrency can all add to the total.

Several things move the figure. The variant is the biggest single factor, with the longer-acting with-DAC form usually priced above the without-DAC form because its chemistry is more involved. Vial size matters too, since larger quantities tend to lower the per-milligram cost. Stated purity, order size, and whether the vendor ships from inside the UK or from abroad all feed into the final price a buyer pays.

What the price cannot tell you is the part you most need to know. It does not confirm which of the two molecules is in the vial, it does not verify the stated purity, and it does not guarantee the contents are sterile. A batch-specific certificate of analysis that names the molecule and confirms its mass is the only document that answers those questions, and plenty of listings do not provide one. We do not link to or recommend any supplier as a source, because naming a vendor implies a level of vetting that is not possible from an editorial position.

The costs that never show up on the invoice

The sticker price is not the real cost. Selling and promoting an unlicensed medicine to the public in the UK is restricted, and the MHRA has warned businesses directly about marketing unlicensed weight-management and similar products to consumers^[2]. A buyer has no consumer protection if an order fails to arrive or turns up mislabelled, a shipment can be held at the border, and there is no pharmacist to catch an interaction and no recall if a batch is wrong.

For anyone who competes, there is a further cost. CJC-1295 is prohibited in and out of competition under the World Anti-Doping Agency code as a growth-hormone-releasing factor, in the same group as sermorelin and tesamorelin, and validated methods to detect it in anti-doping samples have been published^[4]. A positive test does not care what the vial cost.

Then there is the part no price captures at all. The published human evidence on CJC-1295 is two small early-phase studies in healthy adults from 2006^[1]. There is no long-term safety dataset, no chronic-dosing profile, and no data in the older or clinical populations where growth-hormone-axis peptides are often discussed. Buying the compound cheaply does not shrink those unknowns.

Where this leaves a UK reader

The short version is that CJC-1295 has no UK price in any regulated sense. What it has is a cash market with a headline of a few tens of pounds per vial and a long list of costs sitting underneath it: the labelling trap between the two molecules, the absence of any quality guarantee, the legal and customs exposure, the anti-doping ban, and a human evidence base that stops in 2006. If you are weighing this up, the sensible next step is a conversation with a clinician who knows your history, not a checkout page. For the wider picture, see CJC-1295 regulatory status by country and the UK regulation overview.